Previous 10 | Next 10 |
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the re-launch of over-the-counter (OTC) Famotidine Tablets USP, 10 mg and 20 mg, the store-brand equivalent...
Dr. Reddy’s Laboratories (RDY) and The Russian Direct Investment Fund ((RDIF)) says they have received approval from the Drug Control General of India ((DCGI)) to initiate an adaptive phase 2/3 human clinical trial for Sputnik V vaccine in India.The study’s p...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and Russian Direct Investment Fund (RDIF), Russia’s sovereign wealth fund, today announced that they have received approval from the Drug Control General of India (DCGI) to conduct an adaptive phase 2/3 h...
Earnings call slated for October 28 th @ 5:30 PM IST / 8:00 AM EDT Dr. Reddy's Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the second quarter ended September 30, 2020 on Wednesday, October 28 th , 2020 after the Board Meeting. ...
Dr. Reddy’s Laboratories (RDY) says it will partner with Science Based Targets initiative’s ((SBTi)) to cut its Scope 1 and 2 greenhouse gas emissions by 55% by 2030 from a FY2017-18 base year, which are in line with the latest climate science of limiting global warmin...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has joined the Science Based Targets initiative’s (SBTi) business ambition for 1.5°C, becoming the first Indian and the third Asian pharmaceutical company to have set its Science-Based Targets to fur...
Dr. Reddy’s Laboratories (RDY) announces the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use.Sapropterin Dihydrochloride tablets are indicated to reduce blood phenylalanine levels in adult and paediatric patients with hyperphenylalaninemia due to tetrah...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of a generic version of Sapropterin Dihydrochloride Tablets, for Oral Use. “We are pl...
Dr. Reddy’s Laboratories (RDY) announces the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Amgen's Sensipar (cinacalcet) Tablets. According to IQVIA Health, the Sensipar had U.S. sales of ~$312M for twelve months ended July 2020. Dr. Reddy’s Cinacalce...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Cinacalcet Tablets, a therapeutic equivalent generic version of Sensipar (cinacalcet) Tablets...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...